RESUMO
Neurodegenerative diseases (NDs), particularly dementia, provide significant problems to worldwide healthcare systems. The development of therapeutic materials for various diseases has a severe challenge in the form of the blood-brain barrier (BBB). Transdermal treatment has recently garnered widespread favor as an alternative method of delivering active chemicals to the brain. This approach has several advantages, including low invasiveness, self-administration, avoidance of first-pass metabolism, preservation of steady plasma concentrations, regulated release, safety, efficacy, and better patient compliance. Topics include the transdermal method for therapeutic NDs, their classification, and the mechanisms that allow the medicine to enter the bloodstream through the skin. The paper also discusses the obstacles and potential outcomes of transdermal therapy, emphasizing the benefits and drawbacks of different approaches.
Assuntos
Administração Cutânea , Barreira Hematoencefálica , Sistemas de Liberação de Medicamentos , Transtornos Mentais , Doenças Neurodegenerativas , Humanos , Doenças Neurodegenerativas/tratamento farmacológico , Doenças Neurodegenerativas/metabolismo , Transtornos Mentais/tratamento farmacológico , Animais , Barreira Hematoencefálica/metabolismo , Sistemas de Liberação de Medicamentos/métodos , Pesquisa Translacional Biomédica/métodos , Ensaios Clínicos como Assunto , Pele/metabolismo , Absorção CutâneaRESUMO
The bidirectional communication between the brain and peripheral organs have been widely documented, but the impact of visceral adipose tissue (VAT) dysfunction and its relation to structural and functional brain changes have yet to be fully elucidated. This review initially examines the clinical evidence supporting associations between the brain and VAT before visiting the roles of the autonomic nervous system, fat and glucose metabolism, neuroinflammation, and metabolites. Finally, the possible effects and potential mechanisms of the brain-VAT axis on the pathogenesis of Alzheimer's disease are discussed, providing new insights regarding future prevention and therapeutic strategies.
Assuntos
Doença de Alzheimer , Gordura Intra-Abdominal , Tecido Adiposo , Doença de Alzheimer/metabolismo , Encéfalo , Humanos , Gordura Intra-Abdominal/metabolismo , Gordura Intra-Abdominal/patologiaRESUMO
Parkinson's disease (PD) is a common central nervous system disorder (CNS) characterized by cell loss in the substantia nigra. Severe loss of dopaminergic neurons and Lewy body formation with α-synuclein inclusions are the main neuropathological features of PD. There's currently no cure for PD, but treatments are available to help relieve the symptoms and maintain quality of life. However, the variety of clinically available therapeutic molecules is mainly limited to treating symptoms rather than halting or reversing disease progression via medical interventions. As an emerging drug carrier, hydrogels loaded with therapeutic agents and cells are attracting attention as an alternative and potentially more effective approach to managing PD. The current work highlights applications of hydrogel-based biomaterials in cell culture and disease modeling as carriers for cells, medicines, and proteins as PD therapeutic models.
Assuntos
Doença de Parkinson , Sistemas de Liberação de Medicamentos , Humanos , Hidrogéis/uso terapêutico , Doença de Parkinson/metabolismo , Qualidade de Vida , Substância Negra/metabolismo , alfa-Sinucleína/metabolismoRESUMO
Neurodegenerative disorders are distinguished by the gradual deterioration of the nervous system's structure and function due to oxidative stress, mitochondrial dysfunction, protein misfolding, excitotoxicity, and neuroinflammation. Among these NDs, Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis characterized an increasing dysfunction and loss of neuronal structure leading to neuronal cell death. Although there is currently no drug to totally reverse the effects of NDs, such novel formulations and administration routes are developed for better management and nose-to-brain delivery is one of delivery for treating NDs. This review aimed to highlight advances in research on various lipid based nanocarriers such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, and cubosomes which are reported to treat and alleviate the symptoms of NDs via nose-to-brain route. The challenges during clinical translation of lipid nanocarriers from bench to bed side is also discussed.
Assuntos
Doenças do Sistema Nervoso Central , Nanopartículas , Encéfalo/metabolismo , Doenças do Sistema Nervoso Central/tratamento farmacológico , Doenças do Sistema Nervoso Central/metabolismo , Sistemas de Liberação de Medicamentos , Humanos , Lipídeos/química , LipossomosRESUMO
Within the last two decades, several members of the Coronaviridae family demonstrated epidemic potential. In late 2019, an unnamed genetic relative, later named SARS-CoV-2 (COVID-19), erupted in the highly populous neighborhoods of Wuhan, China. Unchecked, COVID-19 spread rapidly among interconnected communities and related households before containment measures could be enacted. At present, the mortality rate of COVID-19 infection worldwide is 6.6%. In order to mitigate the number of infections, restrictions or recommendations on the number of people that can gather in a given area have been employed by governments worldwide. For governments to confidently lift these restrictions as well as counter a potential secondary wave of infections, alternative medications and diagnostic strategies against COVID-19 are urgently required. This review has focused on these issues.
Assuntos
COVID-19 , Epidemias , China , Humanos , SARS-CoV-2RESUMO
Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder which is associated with the accumulation of proteotoxic Aß peptides, and pathologically characterized by the deposition of Aß-enriched plaques and neurofibrillary tangles. Given the social and economic burden caused by the rising frequency of AD, there is an urgent need for the development of appropriate therapeutics. Natural compounds are gaining popularity as alternatives to synthetic drugs due to their neuroprotective properties and higher biocompatibility. While natural compound's therapeutic effects for AD have been recently investigated in numerous in vitro and in vivo studies, only few have developed to clinical trials. The present review aims to provide a brief overview of the therapeutic effects, new insights, and upcoming perspectives of the preclinical and clinical trials of flavonoids for the treatment of Alzheimer's disease.
RESUMO
Neurodegenerative diseases (NDs) such as dementia, Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis are some of the most prevalent disorders currently afflicting healthcare systems. Many of these diseases share similar pathological hallmarks, including elevated oxidative stress, mitochondrial dysfunction, protein misfolding, excitotoxicity, and neuroinflammation, all of which contribute to the deterioration of the nervous system's structure and function. The development of diagnostic and therapeutic materials in the monitoring and treatment of these diseases remains challenging. One of the biggest challenges facing therapeutic and diagnostic materials is the blood-brain barrier (BBB). The BBB is a multifunctional membrane possessing a plethora of biochemical, cellular, and immunological features that ensure brain homeostasis by preventing the entry and accumulation of unwanted compounds. With regards to neurodegenerative diseases, the recent application of tailored nanomaterials (nanocarriers and nanoparticles) has led to advances in diagnostics and therapeutics. In this review, we provide an overview of commonly used nanoparticles and their applications in NDs, which may offer new therapeutic strategies for the prevention and treatment of neurodegenerative diseases.
Assuntos
Doença de Alzheimer , Nanopartículas , Doenças Neurodegenerativas , Humanos , Doenças Neurodegenerativas/diagnóstico , Doenças Neurodegenerativas/tratamento farmacológico , Doença de Alzheimer/diagnóstico , Doença de Alzheimer/tratamento farmacológico , Encéfalo/metabolismo , Barreira Hematoencefálica/metabolismo , Nanopartículas/uso terapêutico , Nanopartículas/químicaRESUMO
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia. Traditional medicinal plants with antidiabetic properties can be used as drugs or dietary adjuvants to existing therapies. This chapter presents the preparation of aqueous and ethanol extracts of Adenosma bracteosum Bonati (A. bracteosum) and evaluation of these for antioxidant and α-glucosidase inhibition activities in vitro. In addition, we tested the extracts and the purified A. bracteosum compound (isoscutellarein 8-O-ß-D-glucopyranoside) for antihyperglycemic effects in glucose-loaded hyperglycemic and streptozotocin (STZ)-induced diabetic mice.
Assuntos
Diabetes Mellitus Experimental , Hiperglicemia , Animais , Glicemia , Diabetes Mellitus Experimental/induzido quimicamente , Diabetes Mellitus Experimental/tratamento farmacológico , Hipoglicemiantes/farmacologia , Camundongos , Extratos Vegetais/farmacologia , Estreptozocina/toxicidadeRESUMO
The Bouea macrophylla (B. macrophylla) tree is widely grown throughout South East Asia and has been used as a traditional medicine for the treatment of various illnesses. This chapter presents a protocol for preparation of ethanol extracts of B. macrophylla leaves and evaluation of the potential antimicrobial and anticancer activities in vitro. The extract displayed antibacterial activity against nine out of the ten target microorganisms tested. In addition, the extract was capable of inhibiting the proliferation of HeLa and HCT116 cells, thus demonstrating some anticancer activity.
Assuntos
Anacardiaceae , Anti-Infecciosos , Antineoplásicos , Extratos Vegetais , Anacardiaceae/química , Antibacterianos/farmacologia , Anti-Infecciosos/farmacologia , Antineoplásicos/farmacologia , Etanol , Humanos , Extratos Vegetais/farmacologia , Folhas de PlantaRESUMO
Liver cancer is the most frequent cancer, making it the leading cause of cancer death globally. Traditional medicinal plants with anticancer properties can be used as drugs or dietary adjuvants to existing therapies. This chapter presents a protocol for the preparation of ß-sitosterol and ß-sitosterol-glucoside from Indigofera zollingeriana Miq (I. zollingeriana) and the evaluation of these for anticancer activity in hepatocellular cells.
Assuntos
Carcinoma Hepatocelular , Indigofera , Neoplasias Hepáticas , Carcinoma Hepatocelular/tratamento farmacológico , Glucosídeos/farmacologia , Humanos , Neoplasias Hepáticas/tratamento farmacológico , Extratos Vegetais/farmacologia , SitosteroidesRESUMO
Drug delivery to central nervous system (CNS) diseases is very challenging since the presence of the innate blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier that impede drug delivery. Among new strategies to overcome these limitations and successfully deliver drugs to the CNS, nanotechnology-based drug delivery platform, offers potential therapeutic approach for the treatment of some common neurological disorders like Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease. This review aimed to highlight advances in research on the development of nano-based therapeutics for their implications in therapy of CNS disorders. The challenges during clinical translation of nanomedicine from bench to bed side is also discussed.